Gautam Sanyal is a scientific leader in development of analytical and biophysical methods that are essential to batch release and characterization of vaccines and biopharmaceuticals. His expertise extends to rational formulation design, as demonstrated by delivery of several safe and effective formulations to clinical trials for recombinant protein based VLPs and attenuated viral vaccines as well as therapeutic proteins and oncolytic viruses. More recently, Gautam has been involved in advisory roles on projects emerging from the newer vaccine technologies, with a focus on analytical characterization and assays for mRNA and viral vectored vaccines. Apart from his extensive work on vaccines and biologics, Gautam led biochemistry, biophysics and protein science teams in target- based discovery of antibacterial therapeutics. He has published extensively research papers, book chapters and review articles. During the 27 years that Gautam spent in pharmaceutical industry, he headed R&D departments and groups at Merck, AstraZeneca and MedImmune (AstraZeneca Biopharmaceuticals). For the past several years, Gautam has focused his efforts on global health initiatives. He is a CMC Subject Matter Expert with the Bill and Melinda Gates Foundation and has been associated with other global health organizations such as CEPI and PATH. Gautam also serves in the faculty of the Global Training Hub for Biomanufacturing (GTH-B) at the International Vaccine Institute.
How are we improving our understanding of RNA technology for next generation vaccines? How will RNA transform therapeutics and cancer treatment?
10:00 Chair opening remarks
10:10 mRNA vaccines of the future: Bridging the Knowledge GapsDr Sudha Chivukula, AVP, Head of Discovery Biology, mRNA Centre of Excellence, Sanofi
10:25 Beyond respiratory vaccines Dr Jacqueline Miller, SVP, Therapeutic Area Head - Infectious Disease Development, Moderna
10:45 Individualized mRNA vaccines Ruben Rizzi, Senior Vice President Global Regulatory Affairs, BioNtech
11:15 Analytical challenges in characterization of multivalent mRNA vaccinesDr Gautam Sanyal, Principal Consultant and Founder, Vaccine Analytics, LLC
11:30 RNABL: A Novel RNA Delivery Platform for Therapeutic ApplicationsDr Micheal Breen, Scientist, Tiba Biotech
11:45 From a preventive vaccine to a therapeutic vaccineDr Jason Zhang, CEO and Co-Founder, ZipCode Bio
12:00 – 1:00 Panel: Beyond prophylactic vaccines: the future of RNA therapeutics
Moderator: Anna Rose Welch, Editorial and Community Director, Advancing RNA, Life Science Connect Dr Gilles Besin, CSO, Orbital Therapeutics Dr Gopi Shanker, CSO, Beam Therapeutics Dr Andrew Geall, Chief Development Officer, Replicate Bioscience